$ 4.33
Key Takeaways
Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and...
Company Valuation
Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers.
Target Price
The average target price of ANIX is 9.6 and suggests 122% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increa
